The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues by Tel, Jurjen et al.
ORIGINAL ARTICLE
The chemotherapeutic drug oxaliplatin differentially affects blood
DC function dependent on environmental cues
Jurjen Tel • Stanleyson V. Hato • Ruurd Torensma •
Sonja I. Buschow • Carl G. Figdor •
W. Joost Lesterhuis • I. Jolanda M. de Vries
Received: 27 October 2011/Accepted: 9 December 2011/Published online: 23 December 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract It has become evident that the tumor microen-
vironment plays a pivotal role in the maintenance of can-
cerous growth. One of the acquired functions of the tumor
microenvironment is the suppression of immune responses.
Indeed, blocking the inhibitory pathways operational in the
microenvironment results in enhanced T-cell-dependent,
anti-tumor immunity. Chemotherapeutic drugs not only
directly kill tumor cells but also shape the tumor micro-
environment and potentiate anti-tumor immunity. Here, we
demonstrate that the chemotherapeutic compound oxalipl-
atin acts as a double-edged sword. Besides killing tumor
cells, oxaliplatin bolsters immunosuppressive pathways,
resulting in decreased activation of T cells by human
plasmacytoid dendritic cells (pDCs). Exposure to oxalipl-
atin markedly increased expression of the T-cell inhibitory
molecule programmed death receptor-ligand 1 (PD-L1) on
human pDCs and also TLR9-induced IFNa secretion.
Furthermore, oxaliplatin decreased TLR-induced STAT1
and STAT3 expression, and NF-jB-mediated responses.
The oxaliplatin induced upregulation of PD-L1 and
downregulation of costimulatory molecules CD80 and
CD86 resulted in decreased T-cell proliferation. Our results
demonstrate that platinum-based anticancer drugs adapt
TLR-induced signaling in human pDCs and myeloid DCs
(mDCs), thereby downgrading their immunostimulatory
potential.
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Abbreviations
DC Dendritic cell
moDC Monocyte-derived DC
mDC Myeloid DC
pDC Plasmacytoid DC
PD-1 Death receptor 1
PD-L1 Program death ligand 1
Introduction
Dendritic cells (DCs) are the most potent professional
antigen-presenting cells (APC) of the immune system.
Upon infection or inﬂammation, immature DCs are acti-
vated and differentiate into mature DCs that instruct and
activate B and T lymphocytes, the mediators of adaptive
immunity [1]. Two major types of DCs circulate in
peripheral blood, myeloid DCs (mDCs) and plasmacytoid
(pDCs). These DC subsets express a divergent set of sur-
face molecules and have distinct functions [2]. In addition
to scavenging pathogens and presenting antigens, DCs
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proper functioning of both the acquired and the innate
immune system.
Although these DC subsets reside in the peripheral
blood, they also inﬁltrate solid tumors, such as breast
cancer [3], head and neck cancer [4] and ovarian cancer
[5]. Soluble factors secreted by the tumor and necrotic
tumor material prevent differentiation and activation of
inﬁltrating DCs, including pDCs [6–8]. These ﬁndings
have been correlated with poor prognosis [3, 9]. Further-
more, Curiel et al. demonstrated that in human ovarian
cancer, inﬁltrating DCs express the immunosuppressive
receptor program death ligand 1 (PD-L1 also known as B7-
H1 or CD274) [10]. PD-L1 negatively regulates the deli-
cate balance between T-cell activation and inhibition
through interaction with its receptor program death recep-
tor 1 (PD-1) resulting in suppressed T-cell activation [11,
12] and maintenance of the immunosuppressive environ-
ment. The negative regulation of T-cell activation via
PD-1/PD-L1 is also supported by studies using blocking
antibodies to PD-L1 performed on DCs [10, 13–15]. The
importance of this pathway is further highlighted in studies
showing that blockade of the PD-1/PD-L pathway results in
enhanced tumor-speciﬁc T-cell expansion and activation
[16, 17]. PDCs and mDCs circulating in the blood do not or
hardly express PD-L1. However, upon TLR-induced acti-
vation or stimulation with type I or type II IFNs, PD-L1 is
upregulated on pDCs and mDCs [18]. This upregulation
has been linked to decreased T-cell proliferation, IFN-c and
IL-10 secretion [11] and the induction of tolerance and
anergic T cells [12, 19]. Blocking these inhibitory mech-
anisms resulted in enhanced anti-tumor immunity [16, 17].
Recent data show that chemotherapeutic drugs affect not
only the tumor cells but also the immunological tumor
microenvironment resulting in a more robust anti-tumor
response [20, 21]. Widely used cytotoxic drugs such as
doxorubicin, paclitaxel and gemcitabine have been shown
to cause enhanced antigen cross-presentation, T-cell
expansion and T-cell inﬁltration of tumors by to date
unknown molecular mechanisms [22, 23]. Furthermore,
our own studies show that oxaliplatin increased the T-cell
stimulatory potential of monocyte-derived DCs (moDCs)
by impairing the IL-4 induced upregulation of PD-L2
through dephosphorylation of STAT6 [24].
In the present study, we disclose that oxaliplatin has a
different effect on blood DC subsets. We observed that
exposure to platinum-based chemotherapeutics increased
the T-cell inhibitory molecule PD-L1 on TLR9-activated
human pDCs resulting in decreased T-cell proliferation.
Furthermore, platinum-based chemotherapeutics markedly
increased TLR9-induced type I IFN secretion and
decreased the expression of STAT1 and STAT3 and the
secretion of IL-6 and TNFa by human pDCs.
Material and methods
Cells
Buffy coats were obtained from healthy volunteers with
informed consent according to institutional and interna-
tional guidelines. PDCs were puriﬁed by positive isolation
using anti-BDCA-4-conjugated magnetic microbeads, and
BDCA-1 mDCs were puriﬁed using anti-CD1c-conjugated
microbeads (both Miltenyi Biotec, Bergisch-Gladbach,
Germany) after B cell depletion. Thereafter, both cell types
were adjusted to 10
6 cells/ml in X-VIVO-15 (Lonza,
Verviers, Belgium) supplemented with 2% human serum
(Sanquin, Nijmegen, the Netherlands). PDC and mDC
purity was routinely up to 95%, as assessed by double
staining with BDCA-2/CD123 or CD11c/CD1c (all Milt-
enyi Biotec). PDCs were activated through the addition of
5 lg/ml ODN-CpG-C (M362, Axxora, San Diego, CA) or
4 lg/ml R848 (Axxora, San Diego, CA). Monocyte-
derived DCs (moDCs) were generated from adherent
peripheral blood mononuclear cells (PBMCs), by culturing
in the presence of IL-4 (500 U/ml) and GM-CSF (800
U/ml) (both Cellgenix, Freiburg, Germany). Cells were
cultured in X-VIVO 15 medium supplemented with 2% of
human serum and harvested on day 6 as immature DC.
Immature DC or mDCs were activated through the addition
of 4 lg/ml R848 and/or 20 lg/ml Poly I:C (Sigma-
Aldrich). Oxaliplatin was added during DC activation, as
indicated.
Flow cytometry
Purity of pDCs and mDCs after isolation and the phenotype
of the pDC populations were determined by ﬂow cytome-
try. The following primary monoclonal antibodies (mAbs)
and the appropriate isotype controls were used: anti-
BDCA2-PE and CD123-APC (all Miltenyi Biotec);
mIgG1-PE, mIgG1-APC, anti-HLA-ABC-PE (W6/32), anti-
HLA-DR/DP-FITC (Q5/13), anti-CD40-PE, anti-CD80-PE,
anti-CD86-PE, anti-CD86-APC, anti-PD-L1-PE, anti-PD-
L2-PE, (all BD Bioscience Pharmingen, San Diego, CA,
USA); anti-CD83-PE (Beckman Coulter, Mijdrecht, the
Netherlands). Intracellularstainingfor STAT proteins: PDCs
were harvested using TEN harvest buffer and ﬁxed with 4%
formaldehyde by 10-min incubation at 37. Cells were per-
meabilized by incubating with ice-cold 90% methanol for
30 minonice.Permeabilizedcellswerewashedandincubate
with the following primary antibodies: rabbit-polyclonal-
anti-STAT1, rabbit-polyclonal-anti-pSTAT1, rabbit-
polyclonal-anti-STAT2, rabbit-polyclonal-anti-pSTAT2,
rabbit-monoclonal-anti-STAT3, rabbit-monoclonal-anti-
pSTAT3, rabbit-polyclonal-anti-STAT6 (all from Cell Sig-
naling) and goat-polyclonal-anti-pSTAT6 (BD Bioscience).
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mouse-Alexa647 or goat-anti-rabbit-Alexa647 as secondary
antibodies. Mean ﬂuorescence intensity and percentage of
positive cells were determined by ﬂow cytometry on a
FACSCalibur (BD Biosciences, San Jose, CA, USA).
Mixed lymphocyte reaction
Allogeneic peripheral blood lymphocytes (PBLs) were co-
cultured with differently matured pDCs, mDCs and moDCs
in a 96-well round-bottom plate (pDC/PBL ratio 1:20
with 1 * 10
5 PBL). After 4 days of culture, 1 lCi/well
([0.037 MBq]/well; MP Biomedicals, Amsterdam, the
Netherlands) of tritiated thymidine was added for 8 h and
incorporation was measured in a beta-counter. In some
experiments, blocking antibodies against PD-L1 (e-Bio-
science, San Diego, USA) were added to the culture at a
ﬁnal concentration of 10 lg/ml. Normal mouse serum was
used as isotype control. Antibodies against PD-L1 were
preincubated with pDCs for 30 min before adding PBLs.
T-cell proliferation data were normalized to account for
intra-experimental differences.
Cytokine detection
PDCs and mDCs were cultured overnight at a concentra-
tion of 10
5 DCs/100 ll/well in a 96-well round-bottom
plate. Supernatants were collected from DC cultures after
16 h of activation, and IFNa and IL-6 production was
analyzed by murine monoclonal capture and HRP-conju-
gated anti-IFNa antibodies (Bender MedSystems, Vienna,
Austria) or anti-IL-6 Abs (Sanquin, Amsterdam, the
Netherlands) using standard ELISA procedures. TNFa,
RANTES, IP-10 and MIP-1a production was measured
using a human Multiplex kit (Bender MedSystems)
according to manufacturer’s instructions.
Preparation of protein lysates and Western blotting
2 9 10
5 cells were lysed in 20 ll lysis buffer containing
10 mM Tris/HCl pH 7.8, 5 mM EDTA, 50 mM NaCl,
1m MN a 3VO4 10 mM pyrophosphate, 50 mM NaF, 1%
Triton X-100, 1 mM PMSF, 10 lg/ml aprotinin, 10 lg/ml
leupeptin and 1X Roche protease inhibitor cocktail (Roche
Diagnostics Nederland BV, Almere, the Netherlands).
Samples were subjected to polyacrylamide gel electropho-
resis and further processed for Western blot analysis. After
blocking, membranes were incubated with one the follow-
ing antibodies: mouse-monoclonal-anti-b-actin (1:20,000;
Sigma-Aldrich, St. Louis, MO), puriﬁed mouse-anti-
PTP1C/Shp-1 (1:250; BD), rabbit-polyclonal-anti-STAT1,
rabbit-polyclonal-anti-pSTAT1, rabbit-monoclonal-anti-
STAT3 and rabbit-monoclonal-anti-pSTAT3 (all from Cell
Signaling). After washing, the membranes were incubated
with one of the goat-anti-mouseIRDye800CW (LI-COR
Biosciences, Lincoln, NE) or polyclonal goat-anti-rabbi-
tAlexaFluor-680 (Molecular Probes, Eugene, OR) as sec-
ondary antibody and analyzed with the LICOR Odyssey
Imaging system (LI-COR Biosciences). Integrated intensi-
ties were analyzed using Excel (Microsoft Corp., Redmond,
WA).
Statistics
All experiments were performed at least three times and
results are shown as the mean ± SEM. Data sets were
either tested by a Student’s t test or by one-way ANOVA
followed by Newman–Keuls or Dunnett’s multiple com-
parison test.
Results
Oxaliplatin differentially regulates the allostimulatory
capacity of activated human DC subsets
When moDCs were exposed to the platinum-based che-
motherapeutic compound oxaliplatin during activation,
signiﬁcantly higher T-cell proliferation was induced com-
pared to moDCs activated without the addition of oxa-
liplatin (Fig. 1a and [24]). Since oxaliplatin is given
intravenously to cancer patients, this ﬁnding prompted us
to investigate the effect of this drug on blood DC function.
IncontrasttowhatweobservedformoDCs,bothPolyI:C
(TLR3)- and R848 (TLR7/8)-activated CD1c
? mDCs
induced lower allogeneic T-cell proliferation when oxa-
liplatin was present during activation (Fig. 1b). In line with
TLR-activated mDCs, we observed that pDCs activated
with the TLR9 agonist CpG-C in the presence of oxaliplatin
displayed a signiﬁcantly decreased capacity to induce allo-
geneic T-cell responses (Fig. 1c). Intriguingly, this effect
was only observed when pDCs were activated through the
TLR9 signaling pathway using CpG-C but not through
TLR7/8 signaling using the single stranded RNA analog
R848 (Fig. 1c). Oxaliplatin-treated pDCs displayed similar
viability compared to oxaliplatin-treated moDCs (Suppl.
Figure 1A, B), showing that the decreased T-cell prolifer-
ation is not caused by toxicity. Thus, oxaliplatin impairs the
ability of TLR-activated blood DCs but not TLR7-activated
pDCs to induce allogeneic T-cell responses.
Oxaliplatin differentially affects the TLR-induced
cytokine secretion proﬁle of blood DCs
Next, we determined whether oxaliplatin modulates
TLR-induced proinﬂammatory cytokine and chemokine
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oxaliplatin negatively affected the secretion of IL-6, TNF-a,
IP-10 and RANTES by TLR8-activated mDCs (Suppl.
Figure 2A), TLR7-activated pDCs (Fig. 2a) and TLR9-
activated pDCs (Fig. 2b). While oxaliplatin also nega-
tively affected TLR3-induced IP-10 secretion by mDCs, it
had no effect on other cytokine and chemokine secretion
by TLR3-activated mDCs (Suppl. Figure 2B). Further-
more, TLR-induced MIP-1a by mDCs remained unaf-
fected upon oxaliplatin treatment (Suppl. Figure 2A, 2B).
By contrast, oxaliplatin treatment affected TLR-induced
MIP-1a by pDCs (Fig. 2a, b). A putative mechanism for
the observed effects could lie in the modiﬁcation of
upstream players controlling NF-jB activity, since it
controls IL-6, TNFa, RANTES, MIP-1a and IP-10
secretion. Interestingly, we found that oxaliplatin had a
divergent effect on the TLR-induced IFNa secretion by
pDCs. On the one hand, oxaliplatin treatment had no
effect on TLR7-induced IFNa secretion, but it markedly
increased TLR9-induced IFNa secretion by human pDCs
(Fig. 2a, b).
Oxaliplatin modulates the TLR-induced human blood
DC phenotype
The observations that oxaliplatin affects TLR-induced
cytokine secretion and decreased blood DC allostimulatory
capacity prompted us to investigate whether oxaliplatin had
an effect on the phenotype of blood DCs. As expected,
CpG-C, R848 and Poly I:C induced a complete activated
phenotype characterized by upregulation of CD40, CD80,
CD86, CD83, and MHC class I and II (Fig. 3 and Suppl.
Figure 3). Oxaliplatin modestly enhanced TLR-induced
upregulation of CD40 on mDCs, but had no effect on TLR-
induced upregulation of MHC class I and II (Suppl.
Figure 3A, B). Oxaliplatin did not affect expression levels
of CD40 and the molecules MHC class I and II on TLR-
activated pDCs (Suppl. Figure 3C, 3D). However, oxa-
liplatin together with CpG-C signiﬁcantly increased the
expression levels of the maturation marker CD83 (Fig. 3d).
By contrast, R848- and Poly I:C-induced CD83 expression
was decreased after oxaliplatin treatment on pDCs and
mDCs (Fig. 3a–c). While oxaliplatin enhanced R848- and
Fig. 1 Effect of oxaliplatin on
DC allostimulatory capacity.
Proliferation of T cells was
measured by
3H-thymidine
incorporation and depicted as
counts per minute. 1 9 10
5
peripheral blood leukocytes
were stimulated for 4 days with
5 9 10
3 allogeneic a moDCs
activated through the addition of
R848 ? Poly I:C or b CD1c
?
mDCs activated through the
addition of either R848 or Poly
I:C c pDCs activated through
R848 or CpG-C. Where
indicated, DCs were treated
with oxaliplatin during
activation. Data are the mean
values ± SEM of six
measurements of at least three
independent experiments with
different donors (*P\0.05;
**P\0.01; ***P\0.001)
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it impaired CpG-C-induced CD86 upregulation on pDCs
(Fig. 3c, d). Furthermore, oxaliplatin also impaired
R848- and CpG-C-induced CD80 expression on pDCs
(Fig. 3d), although CD80 expression on mDCs and
R848-activated pDCs remained unaffected (Fig. 3a–c).
These ﬁndings demonstrated that oxaliplatin differentially
modulated the TLR3-, TLR7/8- and TLR9-induced blood
DC phenotype.
Enhanced PD-L1 expression on pDCs after oxaliplatin
treatment results in impaired T-cell activation
Besides T-cell stimulatory mechanisms, DCs are also
known to express and utilize a variety of T-cell inhibitory
mechanisms. Previously, we demonstrated that the
enhanced T-cell proliferation was due to the downregula-
tion of PD-L2 receptor expression levels on moDCs [24].
Interestingly, as we evaluated the effect of oxaliplatin on
TLR9-activated pDCs, we found that PD-L1 expression
was increased upon exposure with oxaliplatin (Fig. 4a, b),
while PD-L2 expression and other inhibitory molecules
were not detected under any of the conditions tested
(Fig. 4b and data not shown). By contrast, PD-L1 expres-
sion levels remained unaltered upon TLR3 and TLR7/8
stimulation and oxaliplatin treatment on pDCs and mDCs
(Fig. 4a). Inhibition of PD-L1 signaling pathway by addi-
tion of anti-PD-L1 blocking antibodies rescued the lost
capacity of platinum-treated CpG-C-activated pDCs to
stimulate allogeneic T cells (Fig. 4c). These data support
the observation that upregulation of PD-L1 has a signiﬁ-
cant role on the decreased T-cell stimulatory capacity of
platinum-treatedpDCs.Thus,enhancedPD-L1anddecreased
CD80/CD86 expression on oxaliplatin-treated CpG-C-acti-
vated pDCs impairs T-cell proliferation.
IL-4 counterbalances oxaliplatin-induced TLR
modulation in pDCs
Recently, we showed that pDCs stimulated with IL-4
together with a TLR9 agonist induced stronger allogeneic
T-cell responses than pDCs stimulated solely through
TLR9 [25]. Therefore, we sought to determine whether
IL-4 could restore the decreased allostimulatory capacity of
oxaliplatin-treated pDCs. In accordance with previous
ﬁndings, Fig. 5a illustrates that IL-4 enhanced the allo-
stimulatory capacity of TLR9-activated pDCs. Interest-
ingly, the addition of IL-4 during oxaliplatin treatment
could partially restore the low allogeneic T-cell prolifera-
tion by TLR9-activated pDCs (Fig. 5a). Additionally, we
also observed that IL-4 was able to restore the oxaliplatin-
impaired CD80 and CD86 expression to basal levels
(Fig. 5b). This is in contrast to PD-L1 expression which
remained high upon IL-4 stimulation (Fig. 5b). Besides
inverting the allostimulatory capacity and expression of
surface molecules, IL-4 also reduced the oxaliplatin-
enhanced IFNa secretion (Fig. 5c). These data not only
demonstrate that different environmental factors can
modulate the functionality of TLR9-activated pDCs but
also show that different environmental cues can counteract
each other during TLR9 activation. Furthermore, these data
also show that the balance between stimulatory and
inhibitory signals provided by pDCs has a signiﬁcant effect
on T-cell proliferation (Fig. 5d).
Fig. 2 Oxaliplatin alters the TLR-induced secretory proﬁle in human
pDCs. Supernatants of pDC cultures following incubation with R848
(a) or CpG-C (b) with or without 7 lg/ml oxaliplatin were analyzed
for the presence IL-6, TNFa, IP-10, RANTES, MIP-1a and IFNa. The
graphs show cytokine and chemokine production relative to pDCs
activated in the absence oxaliplatin. Data shown are mean val-
ues ± SEM of at least three independent experiments with different
donors (*P\0.05; **P\0.01)
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Recently, An et al. described that SHP-1 differentially
regulates the production of proinﬂammatory cytokines and
type I interferon [26]. Therefore, we studied the potential
involvement of phosphatases in order to pinpoint the
potential candidate proteins responsible for the observed
dual function of oxaliplatin on pDCs: an enhanced IFNa
secretion and a decreased NF-jB-induced response. We
hypothesized thatoxaliplatin treatmentmight increaseSHP-
1 expression in human TLR9-activated pDCs. In Fig. 6a, it
is shown that SHP-1 expression is induced in human pDCs
upon TLR9 activation with CpG-C. However, oxaliplatin in
combination with CpG-C did not result in signiﬁcant
enhanced SHP-1 expression (Fig. 6a, b). Because the
functional activity of SHP-1 does not have a linear relation
with its expression [27], we also investigated the effect of
SHP-1 inhibition using the inhibitor sodium stibogluconate.
To exclude the involvement of other phosphatases, we also
tested the broad range phosphatase inhibitor suramin [28,
29]. The presence of sodium stibogluconate reduced the
oxaliplatin-induced IFNa secretion, but did not affect oxa-
liplatin-induced CD80, CD86 and PD-L1 expression
(Fig. 6c). Interestingly, there was an increase in the effect of
oxaliplatin in the presence of suramin hinting to the possi-
bility that a phosphatase is involved (Fig. 6c). Another
recent study reported that oxaliplatin activates the NOTCH-
1 pathway by induction of the c-secretase complex [30].
Therefore, we investigated the effect of pDC preincubation
with a c-secretase inhibitor on oxaliplatin-induced effects.
However, this inhibitor did not result in abrogation of the
oxaliplatin-induced effects (data not shown).
Previously, Lesterhuis et al. demonstrated that oxalipla-
tin was able to dephosphorylate STAT6 [24]. That promp-
ted us to investigate whether oxaliplatin also affects STAT
signaling in TLR9-activated pDCs. We showed by both
Western blot and FACS analysis that oxaliplatin reduced
expression levels of total STAT1 and STAT3 in TLR9-
activated human pDCs (Fig. 6d, e). However, total STAT2,
Fig. 3 Oxaliplatin modulates the TLR-induced human blood DC
phenotype. Freshly isolated CD1c
? mDCs and pDCs were activated
overnight with either R848 or Poly I:C, for mDCs, and with R848 or
CpG-C, for pDCs, with or without 7 lg/ml oxaliplatin. Histograms
show the TLR-induced receptor expression levels of the surface
molecules CD80, CD83 and CD86 on pDCs/mDCs (gray ﬁlled)
compared to expression levels of oxaliplatin-treated TLR-activated
pDCs/mDCs (thick black lines) and the appropriate isotype control
(thin black line). Graphs show the receptor expression levels of the
surface molecules CD80, CD83 and CD86 of activated pDCs/mDCs
relative to R848 (a), Poly I:C (b) activated mDCs or R848 (c), CpG-C
(d) activated pDCs. Data shown are mean values ± SEM of at least
three independent experiments with different donors (*P\0.05;
**P\0.01)
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remained unaffected upon oxaliplatin treatment in TLR9-
activated pDCs (Fig. 6d, e). In addition to oxaliplatin, we
also sought to determine the TLR9-induced STAT expres-
sion upon IL-4 exposure. As expected, IL-4 induced the
phosphorylation STAT6 and STAT3, whereas expression
and phosphorylation of other STATs remained unaltered
(Fig. 6e). Besides reducing the expression of total STAT1
and STAT3, oxaliplatin also impaired the IL-4 induced
phosphorylation of STAT6 and STAT3 (Fig. 6e). All
together, these data show that oxaliplatin affects STAT1
and STAT3 expression and TLR9-induced signaling.
Discussion
Recent studies show that besides having a direct cytotoxic
effect on tumor cells, chemotherapeutic drugs can also
potentiate the immune system [20, 21]. Here, we show that
the chemotherapeutic platinum compound oxaliplatin
modulated TLR9-induced signaling in human pDCs. This
modulation led to increased IFNa production, decreased
inﬂammatory cytokine and chemokine secretion, and
decreased STAT1 and STAT3 expression by human pDCs.
Furthermore, we showed that oxaliplatin enhanced PD-L1
expression levels on pDCs, resulting in impaired T-cell
proliferation depending on the maturation stimuli. Gener-
ally, oxaliplatin is used in combination with other cytotoxic
drugs as a treatment regimen for gastrointestinal, colorec-
tal, esophago-gastric and/or pancreatic cancer. However, it
remains to be elucidated whether the other active com-
pounds in these treatment regimens may also affect the
immunogenicity of human DC subsets.
We studied STATs and protein tyrosine phosphatases,
which are key regulators of intracellular signaling as an
obvious mechanism exploited by oxaliplatin to modulate
Fig. 4 TLR9-induced PD-L1
expression is enhanced by
oxaliplatin on human pDCs.
PD-L1 and PD-L2 expression
by pDCs activated overnight
with R848 or CpG-C with or
without 7 lg/ml oxaliplatin.
a Graphs show the PD-L1
receptor expression (MFI) by
TLR-activated pDCs/mDC with
or without oxaliplatin. Data
shown are mean values of at
least three independent
experiments ± SEM.
b Histograms show the
expression levels of PD-L1 and
PD-L2 (dark gray ﬁlled
histograms) compared to
isotype controls (light gray
ﬁlled histograms) on TLR9-
activated pDCs, of one
representative experiment.
c Mixed lymphocyte reaction
with CpG-C-activated pDCs in
the presence or absence of 7 lg/
ml oxaliplatin in the presence of
blocking antibodies against PD-
L1 or control IgG. Data shown
are mean values ± SEM of four
independent experiments
performed with different
donors. The effect of PD-L1
blocking in the various
conditions was compared to
CpG-C-activated pDCs with
IgG control antibodies that was
set to 100% (*P\0.05;
**P\0.01)
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SHP-1 was reported to block TLR-induced production of
proinﬂammatory cytokines by inhibiting the activation of
NF-jB pathway and MAPKs by direct dephosphorylation
[26, 31, 32]. Moreover, An et al. recently described that in
mice SHP-1 increased TLR- and RIG-I-induced type I IFN
production by directly binding to the kinase domain of
IRAK1 and thus inhibiting IRAK1 activity in bone marrow
DCs, peritoneal macrophages and splenic CD11c
? DCs
[26]. We obtained the same observations in the TLR9-
induced cytokine secretion proﬁle after oxaliplatin treat-
ment; however, a role for SHP-1 was excluded based on
experiments which showed that sodium stibogluconate had
no effect. Interestingly, suramin, a broad phosphatase
inhibitor, enhanced the oxaliplatin-induced effects. These
data indicate that oxaliplatin impairs the activity of a certain
phosphatase rather than increasing the expression of a
phosphatase. Besides phosphatases, also kinases are
involved in signaling upon ligand binding by TLRs [33].
Larange ´ et al. demonstrated that using speciﬁc inhibitors for
JNK or JAK upon TLR7 or TLR8 stimulation, signiﬁcant
changes were observed in the expression of certain surface
molecules and the production cytokines [33]. These
ﬁndings underscore that inhibition of mediators involved in
downstream signaling after TLR stimulation has subtle but
signiﬁcant inﬂuences on cell functionality. The observed
increased expression of PD-L1 related to oxaliplatin treat-
ment implicates undesired effects on the immunological
elimination of tumor cells outcome in cancer patients. It
was reported that tumor-inﬁltrating dendritic cells which
express PD-L1 help to maintain the immunosuppressive
environment [10]. PD-L1 expression has also been detected
on the surface of a wide variety of human cancers, including
lung, colon, breast, ovary, renal cell, glioma and melanoma
[13, 34, 35], and has been correlated with poor prognosis
[34, 36–39]. Tumors escape from the host immune system
by attenuation of tumor-speciﬁc T-cell responses via PD-
L1/PD-1 interactions. Normally, PD-L1 expression is con-
trolled by STAT3 and becomes upregulated by tumor cells
and other immune cells upon IFN or IL-6 stimulation [34,
40–43]. Recently, a study showed that chemotherapeutic
agents also induced PD-L1 surface expression in breast
cancer cells and promoted PD-L1-mediated T-cell apopto-
sis [44]. Additionally, we found that other platinum-based
chemotherapeutic also induced PD-L1 and decreased CD80
and CD86 expression on pDCs, and that oxaliplatin also
Fig. 5 IL-4 counterbalances oxaliplatin effects. Freshly isolated
pDCs were activated overnight through CpG-C in the presence or
absence of IL-4 and/or 7 lg/ml oxaliplatin. a Mixed lymphocyte
reaction with CpG-C-activated pDCs in the presence and/or absence
of oxaliplatin and IL-4. Data shown are mean values ± SEM of four
independent experiments performed with different donors and
normalized to CpG-C-activated pDCs. Graphs show the surface
receptor expression of b CD80, CD86 and PD-L1 and c IFNa
secretion by CpG-C-activated pDCs in the presence and/or absence of
oxaliplatin and IL-4. d Model; TLR-9-induced activation of human
pDCs can be altered by the presence of environmental cues, resulting
in an enhanced or decreased expression proﬁle of costimulatory and
co-inhibitory molecules. This converted balance leads to more
tolerogenic or immunogenic pDCs that largely inﬂuence the fate of
the T-cell response (*P\0.05; **P\0.01)
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123induced PD-L1 expression on tumor cells (Suppl. Figure 4).
In summary, the expression of PD-L1 on tumors has a
negative effect on the immunological outcome and is con-
sidered as a key feature of tolerogenic DCs [43].
In the present study, we demonstrated that human pDCs,
treated with oxaliplatin in the presence of TLR9-induced
type I IFN, markedly increased expression levels of PD-L1.
Aspord et al. demonstrated that in breast cancer tumors
CD4
? T cells are present secreting IFNc and IL-13 [45].
These T cells provide an additional source of IFNs which
in combination with chemotherapeutic agents can lead to
enhanced PD-L1 expression on either tumor cells or on
tumor-inﬁltrating pDCs. Moreover, inﬁltration of pDCs
and expression of PD-L1 in severable tumors correlated
with poor prognosis. Recently, Lesterhuis et al. described
that platinum compounds positively affect the immuno-
stimulatory potential of myeloid DCs by impairing the
upregulation of PD-L2 [24]. Together, this demonstrates
that platinum compounds have dissimilar effects on dif-
ferent DC subsets dependent on the presence of environ-
mental cues. In cancer patients, the therapeutic off-target
effect of platinum compounds will depend on the presence
and the amount of the different tumor-inﬁltrating DC
subsets, the TLR expression on those DC subsets, and the
micro-environment in which they reside. Based on the
present study, when tumors are inﬁltrated with high
Fig. 6 Oxaliplatin decreases TLR9-induced STAT1 and STAT3
expression. a 2 9 10
5 cells were left untreated or activated with CpG-C
or activated with CpG-C with or without oxaliplatin (7 lg/ml). After
overnight culture, cells were lysed and SHP-1 expression was
analyzed by Western blot. Data shown are of one representative
experiment. b The graph shows SHP-1 expression by pDCs relative
CpG-C-activated pDCs. SHP-1 expression relative to actin was
quantiﬁed as described in methods. Data shown are mean values of
three independent experiments ± SEM. c PDCs were activated
overnight by CpG-C with or without oxaliplatin and phosphatase
inhibitors where indicated. The graphs show CD80, CD86 and PD-L1
surface expression levels and IFNa secretion by pDCs relative to
CpG-C-activated pDCs. Data shown are mean values of three
independent experiments ± SEM. d Freshly isolated, CpG-C-acti-
vated ± oxaliplatin pDCs were lysed, and total and phosphorylated
STAT1 and STAT3 expression was analyzed by Western blot. One
representative experiment is shown. e Histograms show the expres-
sion of total or phosphorylated STAT1, STAT2, STAT3 and STAT6
after overnight activation with CpG-C (gray ﬁlled; top and middle
row) in the presence of oxaliplatin (thick black lines; top and bottom
row) or IL-4 (thick black lines; middle row: gray ﬁlled; bottom row).
One representative experiment is shown
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123numbers of pDCs, it would be beneﬁcial to provide addi-
tional TLR7-agonists rather than TLR9-agonists in combi-
nation with platinum-based chemotherapeutics. Combining
chemo- with immunotherapy is already reported, show-
ing that combining chemotherapy with immunotherapy
improves patient survival compared to patients treated with
only chemotherapy [46]. However, in order to become even
more effective, therapeutic strategies should have direct
cytotoxic effects but also be tailored based on the presence
of tumor-inﬁltrating DCs and the TLR expression by those
tumor-inﬁltrating DCs. This tailor-made combination of
chemotherapy with additional immunotherapy has great
potential in inducing superior anti-tumor responses and
ultimately will lead to enhanced tumor clearance and patient
survival.
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